BlinkBio Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $525K
Latest Deal Amount
  • Investors
  • 4

BlinkBio General Information

Description

Developer of drug conjugate therapies designed to facilitate the treatment of cancer. The company's therapies use a targeting moiety to selectively deliver toxins inside cancer cells without harming the normal cells, enabling medical practitioners to treat cancer patients with improved safety and efficacy.

Contact Information

Website
www.blinkbioinc.com
Formerly Known As
Coferon, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Alexandria Innovation Center
  • 555 Heritage Drive, Suite 165
  • Jupiter, FL 33458
  • United States
+1 (800) 000-0000

BlinkBio Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BlinkBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 22-Jul-2019 $525K 000.00 Completed Generating Revenue
6. Later Stage VC 19-Apr-2019 00.00 000.00 Completed Generating Revenue
5. Later Stage VC 21-Jul-2017 000.00 000.00 000.00 Completed Generating Revenue
4. Debt - General 04-Mar-2016 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 16-Jul-2012 000.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A2) 13-May-2011 $3M $7.1M 000.00 Completed Startup
1. Early Stage VC (Series A1) 05-Jan-2011 $4.1M $4.1M 000.00 Completed Startup
To view BlinkBio’s complete valuation and funding history, request access »

BlinkBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2 0,000,000 00.000000 00.00 00.00 00.00 00.00
Series A-1 0,000,000 00.000000 00 00 00 00.000
To view BlinkBio’s complete cap table history, request access »

BlinkBio Executive Team (10)

Name Title Board Seat Contact Info
James Schulz Interim Chief Financial Officer
Todd Huffman Ph.D Director of Business Development
Don Bergstrom Ph.D Academic Co-Founder
Colin Goddard Ph.D Chairman & Chief Executive Officer
Francis Barany Ph.D Academic Co-Founder
You’re viewing 5 of 10 executive team members. Get the full list »

BlinkBio Board Members (6)

Name Representing Role Since
Colin Goddard Ph.D Self Chairman & Chief Executive Officer 000 0000
Douglas Reed MD Hatteras Venture Partners Board Member 000 0000
Michael Gargano Argent Ventures Board Member 000 0000
Viren Mehta Ph.D Self Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

BlinkBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BlinkBio Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Florida Institute for the Commercialization of Public Research Not-For-Profit Venture Capital Minority 000 0000 000000 0
Ascent Biomedical Ventures Venture Capital Minority 000 0000 000000 0
Hatteras Venture Partners Venture Capital Minority 000 0000 000000 0
MedImmune Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view BlinkBio’s complete investors history, request access »

Ready to get started?

Request a free trial